31 results found.
    
Orthopedic Public Companies Grow 2.6% YoY in Quarter
.article table {table-collapse: collapse;} .article table {border: 1px solid black !important;margin-bottom: 18px;} .artcle th {border: 1px solid black !important;} .article td {border: 1px solid black !important;} .article tr:last-child .article td {text-align: right;} ....
Vericel Posts Record Growth in 2Q19 on New Surgeons
Vericel reports 2Q19 MACI revenue of USD $20.8MM, +47.5% vs. 2Q18.
Orthopedic Sales in Line with Seasonal Expectations for 1Q19
By Mike Evers The first quarter of 2019 brought modest growth to the orthopedic market, as expected seasonal softness and more competition in digital surgery platforms slowed sales for some of the largest players. The 25 companies listed herein had combined total orthopedic sales of $8....
Vericel Reports 1Q19 MACI Revenue of $16.6MM, +37% vs. 1Q18
Vericel reports 1Q19 MACI revenue of USD $16.6MM, +37% vs. 1Q18.
Revenue Review: 4Q18 and Full Year 2018 Performance Highlights for Public Companies
By Mike Evers Below you’ll find a summary of the major 4Q18 and full year 2018 developments for publicly-traded orthopedic companies. Exhibits 1 and 2 show 4Q18 and full year performance, respectively.  Companies continue to refine their strategies to improve sales mix ...
Vericel Reports 4Q18 MACI Revenue of $25.1MM, +56% vs. 4Q17
Vericel reports 4Q18 MACI revenue of USD $25.1MM, +56% vs. 4Q17, with 2018 full year reven...
Revenue Review: 3Q18 Performance Highlights and 2018 Projections for Public Companies, Continued
By Mike Evers In the exhibits below, we've added nine companies to round out our revenue review for 3Q18. As noted in last month's 
3Q18 and 9 Month 2018 Performance Highlights for Public Companies
By Mike Evers Our recap highlights 3Q18 developments and ORTHOWORLD's projection of 2018 full-year revenue for the first publicly traded orthopaedic companies to report. Exhibits 1 and 2 below show year over year company performance for 3Q18 and nine months ending September 30, 2018...
Vericel Reports 3Q18 MACI Revenue of $16.4MM, +65.7% vs. 3Q17
Vericel posts another record quarter for MACI with revenue of US $16.4MM, +65.7% vs. 3Q...
Revenue Review: 1H18 Growth and 2Q18 Performance Highlights for Public Companies
by Julie A. Vetalice The 21 companies tracked below collectively grew +3.6% in 1H18 vs. 1H17, still on track to reach our estimates of +3.7% in orthopaedic industry growth for 2018 vs. 2017. Exhibits 1 and 2 reflect 1H18 results for public orthopaedic companies. The performan...
Vericel Posts 2Q18 MACI Revenue Growth
For 2Q18, Vericel posted MACI orthobiologic revenue of US $14.1MM, +9.3% vs. 2Q17, with 1H18 revenue of $26.2MM,...
Public Orthopaedic Companies: 1Q18 Revenue and Growth Drivers
By Julie A. Vetalice The 21 companies tracked in Exhibits 1 and 2 collectively grew +3.1% in 1Q18 vs. 1Q17, remaining on track alongside our estimates of +3.7% in orthopaedic industry growth for 2018 vs. 2017. (Review
Vericel Posts MACI 1Q18 Revenue Growth
For 1Q18, Vericel posted orthobiologic revenue of US $12.1MM, +142% vs. 1Q17.
Public Orthopaedic Companies: 2017 Revenue and 2018 Sales Drivers
By Julie A. Vetalice The 20 companies tracked in Exhibits 1 and 2 collectively grew +3.0% in 2017 vs. 2016. Individually, you’ll notice some stellar performance in particular segments. (Our final estimates for 2017 orthopaedic industry revenue can be found in
Vericel Reports Orthobiologics Growth for 4Q17, 2017
Vericel posted 4Q17 orthobiologic revenue of US $16.1MM, +26.8% vs. 4Q16, and 2017 revenue of $43.9MM...
Majority of Public Orthopaedic Companies Still on Track for Full-Year Guidance
By Julie A. Vetalice Looking at 3Q17 revenue and reading call transcripts, much was said about unforeseen headwinds that crept in before the close of the year, affecting orthopaedic companies in a variety of ways. Following weather events, oft-cited “softness&rdqu...
Vericel Reports 3Q17 MACI Revenue +19%
Vericel posted 3Q17 orthobiologic revenue of US $9.9MM, +19.3% vs. 3Q16, and YTD revenue of $27.8MM, +6.5% ...
Sales Results for 20 Orthopaedic Companies: A Mid-year Status Report
By Julie A. Vetalice Now that we’ve collected 1H17 results from 20 publicly-traded companies, I’d like to share some performance-based observations. With now just 4 months remaining in the year, these companies provide a helpful gauge in projecting industry growth.
Vericel Reports 2Q17 Orthobiologic Revenue
Vericel posted 2Q17 orthobiologic revenue of US $12.9MM, +43.4% vs. 2Q16, and 1H17 revenue of $17.9MM, +27.9%
Public and Private Company Revenue Review: 1Q17
By Julie A. Vetalice We're eager to see 2Q17 results to prepare a 1H review for you. In the interim, here are the 1Q17 numbers for publicly-traded companies, with updates and estimates for a number of privately-traded companies, too. Exhibits 1 and 2 illustrate 1Q17 performanc...
Vericel Reports 1Q17 Orthobiologic Revenue
Vericel posted 1Q17 orthobiologic revenue of US $5.0MM, -43.2% vs. 1Q16.
Company Revenue 2016
For these publicly-traded orthopaedic device companies, Exhibits 1 and 2 present 2016 orthopaedic revenue and growth. Exhibit 1 includes links to company's full-year revenue reporting, as well. ...
Vericel Posts 4Q16 and 2016 Revenue
Vericel posted 2016 Carticel revenue of US $38.8MM, +10.2% vs. 2015, with 4Q16 revenue of $12.7MM, +12.4% vs...
Company Revenue 3Q16: A Final Look
By Julie A. Vetalice As we wrap up orthopaedic revenue for the latest reporting period, we observe that Stryker and Zimmer Biomet lead the largest orthopaedic companies in 3Q16 growth:
Vericel Reports 3Q16 Revenue
Vericel posted 3Q16 Carticel revenue of US $8.3MM, +7.8% vs. 3Q15. Carticel is an autologous chondrocyte implant marketed in the ...
  • ORTHOWORLD INC.
  • 8401 Chagrin Road, Suite 18
  • Chagrin Falls, Ohio 44023 USA
  • Phone: 440.543.2101 • Fax: 440.543.2122
  • ©1992-2019 ORTHOWORLD
  • All Rights Reserved.
  • Site Managed By:
  • Open Professional Group